Computational Molecular Biology 2016, Vol.6, No.1, 1-20
18
Morgan M.J., and Liu Z., 2010, Crosstalk of reactive oxygen species and NF- κB signaling. Nature Publishing Group, 21(1): 103–115.
Multhoff G., Molls M., and Radons J., 2011, Chronic inflammation in cancer development. Frontiers in Immunology, 2: 98.
Mund T., Lewis M.J., Maslen S., and Pelham H.R. (2014). Peptide and small molecule inhibitors of HECT-type ubiquitin ligases. PNAS, 111(47): 2–7.
Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet R.J., and Sledge G.W., 1997, Constitutive activation of NF-kappaB during progression of breast cancer to
hormone-independent growth. Molecular and Cellular Biology, 17(7): 3629–39.
Obeng E.A., Carlson L.M., Gutman D.M., Jr W.J.H., Lee K.P., and Boise L.H., 2006, Proteasome inhibitors induce a terminal unfolded protein response in
multiple myeloma cells. Blood, 107(12): 4907–4917.
Oeckinghaus A., Hayden M.S., and Ghosh S., 2011, Crosstalk in NFκB signaling pathways, Nat Immunol., 12(8)
:695-708.
Otvos L., and Wade J.D., 2014, Current challenges in peptide-based drug discovery. Frontiers in Chemistry, Front Chem. 2:62.
Perkins N.D., and Gilmore T.D., 2006, Good cop, bad cop: the different faces of NF-kappaB. Cell Death and Differentiation, 13(5): 759–772.
Pierce N., Tang X., Lomenick B., Damoiseaux R., and Hao R., 2010, Chemical genetics of TOR identifies an SCF family E3 ubiquitin ligase inhibitor. Nature
Biotechnology, 28(7): 738–742.
Pogson M., Holcombe M., Smallwood R., and Qwarnstrom E., 2008, Introducing Spatial Information into Predictive NFkB Modelling – An Agent-Based
Approach, 3(6): 1–6.
Popa C., Netea M.G., Van Riel P.L.C.M., Van Der Meer J.W.M., and Stalenhoef A.F.H., 2007, The role of TNF- in chronic inflammatory conditions,
intermediary metabolism, and cardiovascular risk. The Journal of Lipid Research, 48(4): 751–762.
Qin Z., Tao L., and Chen X., 2007, Dual roles of NF- κ B in cell survival and implications of NF- κ B inhibitors in neuroprotective therapy. Acta Pharmacol Sin
.
28(12): 1859–1872.
Rahman M.M., Mohamed M.R., Kim M., Smallwood S., and Mcfadden G., 2009, Co-Regulation of NFkB and Inflammasome-Mediated Inflammatory
Responses by Myxoma Virus Pyrin Domain-Containing Protein M013, PLoS Pathog
.
5(10):e1000635.
Rakoff-Nahoum S., 2006, Why Cancer and Inflammation. Yale journal of biology and medicine, 79: 123–130.
Ranaweera R.S., and Yang X., 2013, Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity. The Journal of Biological Chemistry, 288(26):
18939–46.
Riley B.E., Lougheed J.C., Callaway K., Velasquez M., Brecht E., Nguyen L., and Johnston J.A., 2013, Structure and function of Parkin E3 ubiquitin ligase
reveals aspects of RING and HECT ligases. Nature Communications, 4:1982.
Rossi M., Rotblat B., Ansell K., Amelio I., Caraglia M., Misso G., and Melino G., 2014, High throughput screening for inhibitors of the HECT ubiquitin E3
ligase ITCH identifies antidepressant drugs as regulators of autophagy
5(5): e1203–12.
Sandborn W.J., 2001, Strategies targeting tumor necrosis factor in Crohn’s disease. Acta Gastro-Enterologica Belgica, 64(2): 170–2.
Sanjo H., Zajonc D.M., Braden R., Norris P.S., and Ware C.F., 2010, Allosteric Regulation of the Ubiquitin:NIK and Ubiquitin:TRAF3 E3 Ligases by the
Lymphotoxin- Receptor. Journal of Biological Chemistry, 285(22): 17148–17155.
Sasiela C.A., Stewart D.H., Kitagaki J., Safiran Y.J., Yang Y., Weissman A.M., and Keefe B.R.O., 2008, Identification of Inhibitors for MDM2 Ubiquitin Ligase
Activity from Natural Product Extracts by a Novel High-Throughput Electrochemiluminescent Screen. Journal of Biomolecular Screening, 3(3): 229–237.
Scheffner M., Kumar S., and Ubr E.D.D., 2014, Mammalian HECT ubiquitin-protein ligases : Biological and pathophysiological aspects. Biochimica et
Biophysica Acta, 1843: 61–74.
Scheffner M., Nuber U., and Huibregtse J.M., 1995, Protein ubiquitination involving an E1–E2–E3 enzyme ubiquitin thioester cascade. Nature, 373(6509):
81–83.
Shih V.F.S., Kearns J.D., Basak S., Savinova O.V., Ghosh G., and Hoffmann A., 2009, Kinetic control of negative feedback regulators of NF- B/RelA
determines their pathogen- and cytokine-receptor signaling specificity. Proceedings of the National Academy of Sciences, 106(24): 9619–9624.
